These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 18451158)

  • 1. Met and c-Src cooperate to compensate for loss of epidermal growth factor receptor kinase activity in breast cancer cells.
    Mueller KL; Hunter LA; Ethier SP; Boerner JL
    Cancer Res; 2008 May; 68(9):3314-22. PubMed ID: 18451158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met.
    Mueller KL; Madden JM; Zoratti GL; Kuperwasser C; List K; Boerner JL
    Breast Cancer Res; 2012 Jul; 14(4):R104. PubMed ID: 22788954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic effect of afatinib with su11274 in non-small cell lung cancer cells resistant to gefitinib or erlotinib.
    Chen G; Noor A; Kronenberger P; Teugels E; Umelo IA; De Grève J
    PLoS One; 2013; 8(3):e59708. PubMed ID: 23527257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid raft localization of EGFR alters the response of cancer cells to the EGFR tyrosine kinase inhibitor gefitinib.
    Irwin ME; Mueller KL; Bohin N; Ge Y; Boerner JL
    J Cell Physiol; 2011 Sep; 226(9):2316-28. PubMed ID: 21660955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of MET activation in determining the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors.
    Rho JK; Choi YJ; Lee JK; Ryoo BY; Na II; Yang SH; Lee SS; Kim CH; Yoo YD; Lee JC
    Mol Cancer Res; 2009 Oct; 7(10):1736-43. PubMed ID: 19808904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Signal transducer and activator of transcription 5b, c-Src, and epidermal growth factor receptor signaling play integral roles in estrogen-stimulated proliferation of estrogen receptor-positive breast cancer cells.
    Fox EM; Bernaciak TM; Wen J; Weaver AM; Shupnik MA; Silva CM
    Mol Endocrinol; 2008 Aug; 22(8):1781-96. PubMed ID: 18550772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer.
    Wang W; Li Q; Takeuchi S; Yamada T; Koizumi H; Nakamura T; Matsumoto K; Mukaida N; Nishioka Y; Sone S; Nakagawa T; Uenaka T; Yano S
    Clin Cancer Res; 2012 Mar; 18(6):1663-71. PubMed ID: 22317763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HGF-independent potentiation of EGFR action by c-Met.
    Dulak AM; Gubish CT; Stabile LP; Henry C; Siegfried JM
    Oncogene; 2011 Aug; 30(33):3625-35. PubMed ID: 21423210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.
    Nakagawa T; Takeuchi S; Yamada T; Nanjo S; Ishikawa D; Sano T; Kita K; Nakamura T; Matsumoto K; Suda K; Mitsudomi T; Sekido Y; Uenaka T; Yano S
    Mol Cancer Ther; 2012 Oct; 11(10):2149-57. PubMed ID: 22844075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tyrosine phosphorylation of p145met mediated by EGFR and Src is required for serum-independent survival of human bladder carcinoma cells.
    Yamamoto N; Mammadova G; Song RX; Fukami Y; Sato K
    J Cell Sci; 2006 Nov; 119(Pt 22):4623-33. PubMed ID: 17062641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphorylated insulin-like growth factor 1 receptor is implicated in resistance to the cytostatic effect of gefitinib in colorectal cancer cells.
    Yang L; Li J; Ran L; Pan F; Zhao X; Ding Z; Chen Y; Peng Q; Liang H
    J Gastrointest Surg; 2011 Jun; 15(6):942-57. PubMed ID: 21479670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer.
    Takeuchi S; Wang W; Li Q; Yamada T; Kita K; Donev IS; Nakamura T; Matsumoto K; Shimizu E; Nishioka Y; Sone S; Nakagawa T; Uenaka T; Yano S
    Am J Pathol; 2012 Sep; 181(3):1034-43. PubMed ID: 22789825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EGFR/Met association regulates EGFR TKI resistance in breast cancer.
    Mueller KL; Yang ZQ; Haddad R; Ethier SP; Boerner JL
    J Mol Signal; 2010 Jul; 5():8. PubMed ID: 20624308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting Hsp90 prevents escape of breast cancer cells from tyrosine kinase inhibition.
    Pashtan I; Tsutsumi S; Wang S; Xu W; Neckers L
    Cell Cycle; 2008 Sep; 7(18):2936-41. PubMed ID: 18769157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. α-Lipoic acid-induced inhibition of proliferation and met phosphorylation in human non-small cell lung cancer cells.
    Michikoshi H; Nakamura T; Sakai K; Suzuki Y; Adachi E; Matsugo S; Matsumoto K
    Cancer Lett; 2013 Jul; 335(2):472-8. PubMed ID: 23507559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostaglandin E2 receptor EP1 transactivates EGFR/MET receptor tyrosine kinases and enhances invasiveness in human hepatocellular carcinoma cells.
    Han C; Michalopoulos GK; Wu T
    J Cell Physiol; 2006 Apr; 207(1):261-70. PubMed ID: 16331686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HER2 oncogenic function escapes EGFR tyrosine kinase inhibitors via activation of alternative HER receptors in breast cancer cells.
    Kong A; Calleja V; Leboucher P; Harris A; Parker PJ; Larijani B
    PLoS One; 2008 Aug; 3(8):e2881. PubMed ID: 18682844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. STAT5b, a Mediator of Synergism between c-Src and the Epidermal Growth Factor Receptor.
    Kloth MT; Laughlin KK; Biscardi JS; Boerner JL; Parsons SJ; Silva CM
    J Biol Chem; 2003 Jan; 278(3):1671-9. PubMed ID: 12429742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatocyte growth factor reduces sensitivity to the epidermal growth factor receptor-tyrosine kinase inhibitor, gefitinib, in lung adenocarcinoma cells harboring wild-type EGFR.
    Yang H; Wang R; Peng S; Chen L; Li Q; Wang W
    Oncotarget; 2016 Mar; 7(13):16273-81. PubMed ID: 26919104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. c-Src activation mediates erlotinib resistance in head and neck cancer by stimulating c-Met.
    Stabile LP; He G; Lui VW; Thomas S; Henry C; Gubish CT; Joyce S; Quesnelle KM; Siegfried JM; Grandis JR
    Clin Cancer Res; 2013 Jan; 19(2):380-92. PubMed ID: 23213056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.